Jeffrey A Bluestone

Title: The Innovations of Jeffrey A Bluestone

Introduction

Jeffrey A Bluestone is a prominent inventor based in Chicago, IL (US). He is known for his significant contributions to the field of immunology, particularly in the development of methods and materials for modulation of immunosuppressive activity. His work has implications for transplant medicine and autoimmune diseases.

Latest Patents

Jeffrey A Bluestone holds a patent titled "Methods and materials for modulation of the immunosuppressive activity." This patent involves the transfer of the binding specificity of the murine OKT3 into a human antibody framework to reduce immunogenicity. The 'humanized' anti-CD3 monoclonal antibody (gOKT3-5) retains all properties of native OKT3, including T cell activation, which has been correlated with severe side effects in transplant recipients. The patent also discloses a single amino acid mutation from leucine to glutamic acid at position 235 in the Fc receptor binding segment of the gOKT3-5 mAb, producing the Glu-235 mAb. Additionally, an amino acid mutation from phenylalanine at position 234 to leucine is also disclosed.

Career Highlights

Throughout his career, Jeffrey A Bluestone has worked with notable companies such as Ortho Pharmaceutical Corporation and Arch Development Corporation. His experience in these organizations has contributed to his expertise in immunology and patent development.

Collaborations

Jeffrey has collaborated with esteemed colleagues, including Robert Allan Zivin and Linda K Jolliffe. These partnerships have furthered his research and innovation in the field.

Conclusion

Jeffrey A Bluestone's contributions to immunology through his patent and collaborations highlight his role as a significant inventor in the field. His work continues to influence advancements in medical science and patient care.